Skip to content

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06252129
Enrollment
160
Registered
2024-02-09
Start date
2024-07-26
Completion date
2027-12-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Lymph Node Metastasis, Pathologic Processes

Keywords

NSCLC, Lymph node dissection, Lung cancer staging

Brief summary

Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.

Detailed description

Anatomic lung resection with systematic mediastinal lymph node dissection is the standard of care for patients with clinical stage I or II non-small cell lung cancer (NSCLC). While the best type of resection may sometimes be debated, it is clear that mediastinal, hilar, and lobar lymph nodes (LNs) should be routinely retrieved to achieve a complete lung cancer resection. According to major international guidelines, at least 3 hilar/intrapulmonary stations and 3 mediastinal stations should be assessed during resection. Although there is still a debate over whether the ideal number of LN stations sampled or the total number of LNs removed per station provides a better analysis, radical systematic LN dissection seems to offer the best oncological outcomes. In fact, in patients with tumors ≤4 cm in diameter completely resected, the quality of the mediastinal lymph node dissection and the thoroughness of the examination of the surgical specimen will select candidates for adjuvant treatment and define oncologic prognosis. The consequences of an incorrect lymph node classification can be substantial: while patients with N0 NSCLC have approximately 75% 5-year overall survival (OS), patients with NSCLC classified as N1 have a 5-year OS of 49%, and patients with NSCLC classified as N2 a 5-year OS of 36%. Therefore, the burden of determining the correct prognosis lies on the surgeon to perform a rigorous and thorough oncological resection, and on the pathologist to fully assess enough intrapulmonary LNs. Inaccuracy by either specialist leads to pathologic understage and suboptimal clinical management, which will lead to poor patient outcomes. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.

Interventions

OTHERSubjects undergoing a lung specimen lymph node dissection

A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team. The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging.

OTHERControl group

Control group

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Subjects with a lung nodule or mass who are eligible to undergo a lobectomy. 2. Subject without any metastasis present. 3. Subjects who have peripheral lung nodule location 4. Subjects must be 18 years of age or older.

Exclusion criteria

1. Subjects who received preoperative chemotherapy or radiotherapy. 2. Subjects who have a lung nodule located in a central location. Central tumors are defined by those infiltrating the lobar airway.

Design outcomes

Primary

MeasureTime frameDescription
Number of lymph nodes sampled2 weeksTo compare the number of stations and lymph nodes sampled when adopting a standardized technique compared to the conventional (prior) technique.
Nodal upstage rate2 weeksDetermine the number of cases upstaged to N1 with the intrapulmonary lymph node dissection compared to the conventional technique.

Secondary

MeasureTime frameDescription
3y RFS3 yearsThree years recurrence-free survival rate of patients undergoing standardize dissection versus conventional technique.

Countries

United States

Contacts

CONTACTPaula Ugalde Figueroa, M.D.
pugaldefigueroa@bwh.harvard.edu(617) 732-7696

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026